Shuffle Master Results Support Thesis and 4 Stock Analyses Buzzing Now

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Conns Inc. (NASDAQ:CONN) business drivers are believed by Piper Jaffray to continue to be strong heading into 2013. The firm keeps its Overweight rating and increased its price target on the stock.

American Tower Corp. (NYSE:AMT): Morgan Stanley still favors tower stocks and believes that there is an earnings upside from strong leasing trends and acquisitions. The firm has increased its price targets for Overweight rated American Tower to $85 from $73, Crown Castle (NYSE:CCI) to $75 from $65, and SBA Communications (NASDAQ:SBAC) to $77 from $70.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

SanDisk Corp. (NASDAQ:SNDK): Morgan Stanley continues to be bullish on NAND outlook considering its strong demand and low supply growth, and it predicts that SanDisk shares will see benefits from easy comps, yen depreciation, a ramp at Samsung, and conservative guidance. Shares have an Overweight rating.

Shuffle Master Inc. (NASDAQ:SHFL): According to Brean Capital, the company’s Q4 results have supported their investment thesis which was predicated considering the riseof a recurring revenue steam. The company revealed its plans to enter the US slot market, increasing the firm’s confidence in their thesis. Shares keep their Buy rating and a $19 price target.

Affymax, Inc. (NASDAQ:AFFY): Piper Jaffray has stated that the U.S. Government Accountability Office, or GAO, published a report on December 7 that recommented that Congress require the Department of Health and Human Services to rebase the End Stage Renal Disease, or ESRD, bundle as Erythropoiesis-Stimulating Agent utilization saw a 23 percent decline from 2007 to 2011, which is the year on which the bundle is based. Piper continues to think that a reduction in the bundle has grown more probable and that dialysis providers will probably require more discounts from drug manufacturers. The firm is convinced that this could potentially cause volatility in shares of Affymax, and it recommends purchasing the stock on weakness.

Don’t Miss: Exclusive Interview: Rising Star Aaron Task Molds Yahoo Finance’s Future as Editor-in-Chief.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business